



Attorney Docket No.: 5347.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al

Confirmation No: To be assigned

Serial No.: 09/816721

Group Art Unit: 1652

Filed: March 22, 2001

Examiner: To be assigned

For: Novel Cyclomaltodextrin Glucanotransferase Variants

RECEIVED
DEC 07 2001
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed. The references are as follows:

1. EP 0 802 259 A1
2. WPI Derwent Accession Number 93-103608
3. WPI Derwent Accession Number 95-100943
4. WPI Derwent Accession Number 93-347473
5. WPI Derwent Accession Number 93-308317
6. Abstract of JP Patent no. JP5244945
7. Fujiwara et al., Journal of Bacteriology, Nov. 1992, p. 7478-7481, Vol. 174, No. 22.
8. Sin et al., Journal of Biotechnology 32 (1994) 283-288
9. Kim et al., Biochemistry and Molecular Biology International, Vol. 41, No. 2, February 1997, Pages 227-234.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record

therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.


The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,



Date: September 6, 2001

Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



Attorney Docket No.: 5347.210-US

0598
16X9 / 1652
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al

Confirmation No: To be assigned

Serial No.: 09/816721

Group Art Unit: To be assigned

Filed: March 22, 2001

Examiner: To be assigned

For: Novel Cyclomaltoextrin Glucanotransferase Variants

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box DD
Commissioner for Patents
Washington, DC 20231

RECEIVED
DEC 07 2001
TECH CENTER 1600/2900

Sir:

I hereby certify that the attached correspondence comprising:


1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box DD
Commissioner for Patents
Washington, DC 20231

on September 6, 2001.

Kelley O'Patry
(name of person mailing paper)


(signature of person mailing paper)